Eledon Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Eledon Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $0 | Mar 3, 2017 |
| FY2015 | Dec 31, 2015 | $0 | Mar 10, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.62M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($36.18M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($116.54M) | Aug 14, 2025 |
| FY2023 | Sep 30, 2023 | ($9.91M) | Aug 19, 2024 |
| FY2023 | Jun 30, 2023 | ($65.76M) | Aug 19, 2024 |
| FY2023 | Mar 31, 2023 | ($10.77M) | Aug 19, 2024 |
| FY2023 | Dec 31, 2022 | ($87.97M) | Aug 19, 2024 |
| FY2022 | Dec 31, 2021 | ($34.51M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($22.81M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($16.01M) | Mar 31, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($43.00M) | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | ($88.43M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($36.87M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($18.47M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($16.05M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($14.06M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($13.12M) | Mar 28, 2019 |
| FY2016 | Dec 31, 2016 | ($3.76M) | Mar 3, 2017 |
| FY2016 | Sep 30, 2016 | ($9.31M) | Mar 3, 2017 |
| FY2016 | Jun 30, 2016 | ($13.58M) | Mar 3, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.27M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $51.96M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $30.31M | Aug 14, 2025 |
| FY2023 | Dec 31, 2022 | $27.08M | Aug 19, 2024 |
| FY2022 | Dec 31, 2021 | $23.74M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.13M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $8.13M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.82M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $2.02M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $3.19M | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($62.34M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($47.27M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($39.53M) | Aug 14, 2025 |
| FY2023 | Sep 30, 2023 | ($30.40M) | Aug 19, 2024 |
| FY2023 | Jun 30, 2023 | ($18.15M) | Aug 19, 2024 |
| FY2023 | Dec 31, 2022 | ($28.42M) | Aug 19, 2024 |
| FY2022 | Dec 31, 2021 | ($28.91M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($15.21M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($13.86M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($11.89M) | Mar 17, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2016 | $9.0K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $565.0K | Mar 3, 2017 |
| FY2016 | Dec 31, 2014 | $25.0K | Mar 3, 2017 |
| FY2015 | Dec 31, 2013 | $23.0K | Mar 10, 2016 |
| FY2014 | Dec 31, 2012 | $8.0K | Mar 26, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $169.01M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $177.41M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $89.07M | Aug 14, 2025 |
| FY2023 | Dec 31, 2022 | $92.79M | Aug 19, 2024 |
| FY2022 | Dec 31, 2021 | $170.55M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $197.19M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $10.93M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $17.03M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $20.89M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.20M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.23M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $59.27M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $81.86M | Aug 14, 2025 |
| FY2023 | Sep 30, 2023 | $60.47M | Aug 19, 2024 |
| FY2023 | Jun 30, 2023 | $63.02M | Aug 19, 2024 |
| FY2023 | Dec 31, 2022 | $8.61M | Aug 19, 2024 |
| FY2022 | Dec 31, 2021 | $6.55M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.59M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.47M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.53M | Mar 17, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.09M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $62.45M | Mar 19, 2026 |
| FY2024 | Sep 30, 2024 | $20.36M | Aug 14, 2025 |
| FY2024 | Jun 30, 2024 | ($64.20M) | Aug 14, 2025 |
| FY2024 | Mar 31, 2024 | ($70.42M) | Aug 14, 2025 |
| FY2025 | Dec 31, 2023 | ($48.49M) | Mar 19, 2026 |
| FY2023 | Sep 30, 2023 | $35.60M | Aug 19, 2024 |
| FY2023 | Jun 30, 2023 | $43.77M | Aug 19, 2024 |
| FY2023 | Mar 31, 2023 | $74.79M | Aug 19, 2024 |
| FY2024 | Dec 31, 2022 | $23.79M | Aug 14, 2025 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Aug 19, 2024 |
| FY2023 | Dec 31, 2022 | $0 | Aug 19, 2024 |
| FY2023 | Dec 31, 2021 | $48.65M | Aug 19, 2024 |
| FY2022 | Dec 31, 2020 | $48.65M | Mar 30, 2023 |
| FY2019 | Dec 31, 2018 | $1.87M | Mar 17, 2020 |
| FY2019 | Dec 31, 2017 | $1.87M | Mar 17, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($401.20M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($355.59M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($319.40M) | Aug 14, 2025 |
| FY2023 | Sep 30, 2023 | ($289.30M) | Aug 19, 2024 |
| FY2023 | Jun 30, 2023 | ($279.40M) | Aug 19, 2024 |
| FY2023 | Dec 31, 2022 | ($202.87M) | Aug 19, 2024 |
| FY2022 | Dec 31, 2021 | ($114.90M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($80.39M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($57.58M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($41.57M) | Mar 17, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.81M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $20.55M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $4.61M | Aug 14, 2025 |
| FY2023 | Dec 31, 2022 | $56.41M | Aug 19, 2024 |
| FY2022 | Dec 31, 2021 | $84.83M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $114.20M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $8.79M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $12.97M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $17.23M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.10M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Aug 19, 2024 |
| FY2023 | Jun 30, 2023 | (2) | Aug 19, 2024 |
| FY2023 | Dec 31, 2022 | (6) | Aug 19, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Aug 19, 2024 |
| FY2023 | Jun 30, 2023 | (2) | Aug 19, 2024 |
| FY2023 | Dec 31, 2022 | (6) | Aug 19, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 75.43M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 59.79M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 24.21M | Aug 14, 2025 |
| FY2023 | Dec 31, 2022 | 13.78M | Aug 19, 2024 |
| FY2022 | Dec 31, 2021 | 14.31M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 15.16M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | 720,408 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 9.42M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | 7.11M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 394,306 | Apr 2, 2018 |